BioSpace News Archive

Although “off-label” use of drugs approved for a different indication is routine in medical practice, there was an early, aggressive campaign against such use for COVID-19, writes infectious disease specialist Wendell W. Hoffman, M.D., in the spring issue of the Journal of American Physicians and Surgeons.

Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that tegoprubart, the company’s investigational anti-CD40L antibody, was used as a component of the immunosuppressive treatment regimen following the first-ever transplant of a kidney from a genetically modified pig to a human.

The global clinical trials market was evaluated at USD 51.17 billion in 2023 and is expected to attain around USD 83.55 billion by 2032, growing at a CAGR of 5.6% from 2023 to 2032.

Scientists from Cognigenics have made significant progress in developing precision-based therapeutics for neurological disorders.

MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer, today announced the appointment of Jonathan Chriqui, PharmD, as Chief Business Officer and member of the executive management team.

XPlan.ai, a spinoff of RSIP Vision that uses AI to democratize precision orthopedics, reaches a new milestone for its X-ray based 3D bone modeling system with the publication of a peer-reviewed clinical study confirming unprecedented, sub-mm accuracy in a variety of clinically relevant measurements.

Bioretec Ltd., a pioneer in biodegradable orthopedic implants, has been allowed a patent by the U.S. patent office for its RemeOs™ magnesium alloy composition.

NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced the results of the vote held during today’s Special Meeting of Shareholders.

Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.

Hyperfine, Inc. announced fourth quarter and full year 2023 financial results and provided a business update.